Jersey

MISUSE OF DRUGS (DESIGNATION) (JERSEY) ORDER 1989

Official Consolidated Version

This is an official version of consolidated legislation compiled and issued under the authority of the Legislation (Jersey) Law 2021.

08.680.40

Showing the law from 1 December 2021 to Current

MISUSE OF DRUGS (DESIGNATION) (JERSEY) ORDER 1989

Contents

Article

1 Specified drugs 5
2 Citation 5

SCHEDULE **6**

PART 1 6

CONTROLLED DRUGS TO WHICH ARTICLE 12(4) OF THE LAW APPLIES 6

PART 2 15

CONTROLLED DRUGS EXCEPTED FROM PART 1 15

ENDNOTES **16**

Table of Legislation History 16
Table of Renumbered Provisions 17
Table of Endnote References 17

Jersey

MISUSE OF DRUGS (DESIGNATION) (JERSEY) ORDER 1989

THE HEALTH AND SOCIAL SERVICES COMMITTEE, in pursuance of Articles 12 and 27 of the Misuse of Drugs (Jersey) Law 1978 and after consultation with the Advisory Council on the Misuse of Drugs, orders as follows –

Commencement [see endnotes]

1 Specified drugs

(1) The controlled drugs specified in Part 1 of the Schedule are designated as drugs to which Article 12(4) of the Misuse of Drugs (Jersey) Law 1978 applies.

(2) The controlled drugs specified in Part 2 of the Schedule are excepted from Part 1 of that Schedule.

2 Citation

This Order may be cited as the Misuse of Drugs (Designation) (Jersey) Order 1989.

SCHEDULE

PART 1 [1]

CONTROLLED DRUGS TO WHICH ARTICLE 12(4) OF THE LAW APPLIES

1 The following substances and products, namely –

(a) 1,4-butanediol

1-Cyclohexyl-4-(1,2diphenylethyl)piperazine (MT-45)

1-(3,4-Methylenedioxybenzyl)butyl-(ethyl)amine

1-(3,4-Methylenedioxybenzyl)butyl-(methyl)amine

2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

2-(1,4-Dimethoxy-2-naphthyl)ethylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol

2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone (LSZ)

2,5-Dimethoxy-α, 4-dimethyl-phenethylamine

2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol (also known as O-desmethyltramadol)

2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

2-Amino-1-(3,4-dimethoxyphenyl)ethanol

2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

3,4-Dichloromethylphenidate (3,4-DCMP)

3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)

4-Bromo- β,2,5-trimethoxyphenethylamine

4-Bromo-2, 5-dimethoxy- methyl-phenethylamine

4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine

4-Methyl-aminorex

4-methylmethylphenidate

4-Methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine (4,4-DMAR)

(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52)

(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)

(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)

(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)

Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Bufotenine

Cathinone

Coca leaf

Concentrate of poppy-straw

Cyclopropylmethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Dihydroetorphine

Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

Ethylnaphthidate

Ethylphenidate

Eticyclidine

Etryptamine

Gamma-butyrolactone

4-hydroxybutanoic acid (4-hydroxy-n-butyric acid; gamma-hydroxybutyric acid)

Isopropylphenidate (IPP or IPPD)

Khat

Lysergamide

Lysergide and other N-alkyl derivatives of lysergamide

Mescaline

Methcathinone

Methylamphetamine

Methylnaphthidate (HDMP-28)

N-adamantyl-1-pentyl-1H-indazole-3-carboxamide (AKB-48)

N-adamantyl-1(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AKB-48)

N-adamantyl-1(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135)

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AB-PINACA)

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA)

N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxyl-amine

N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxyl-amine

N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxyl-amine

N.N-Diethyltryptamine

N.N-Dimethyltryptamine

N-Hydroxy-tenamphetamine

N-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

Propylphenidate

Psilocin

Quinolin-8-yl-1-(5fluoropentyl)-1H-indole-3-carboxylate (5F-pB-22)

Quinolin-8-yl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22)

Quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate (PB-22)

Raw opium

Rolicyclidine

Tenocyclidine

α, α-Dimethyl-3,4-methylenedioxyphenethyl (methyl)amine

α, α-Dimethyl-3,4-methylenedioxyphenethylamine

α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

α-Methyl-4-(methylthio)phenethylamine (also known as 4-Methylthioamphetamine)

α-Methylphenethylhydroxylamine (also known as N-Hydroxyamphetamine)

β -Methoxy-3,4-methylenedioxyphenethylamine

β,2,5-Trimethoxy-4-methylphenethylamine

β,3,4,5-Tetramethoxyphenethylamine;

(b) any compound (not being a compound for the time being specified in sub-paragraph (a)) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say –

(i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure,

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents,

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents,

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;

(c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, α-methylphenethylamine, an N-alkyl-α-methylphenethylamine, α-ethylphenethylamine, or an N-alkyl-α-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;

(d) any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say –

(i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle,

(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups,

(iii) by substitution in the piperidine ring with alkyl or alkenyl groups,

(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups,

(v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group,

(vi) by replacement of the N-propionyl group by another acyl group;

(e) any compound (not being a compound for the time being specified in Part II of this Schedule) that is structurally derived from

pethidine by modification in any of the following ways, that is to say –

(i) by replacement of the 1-methyl group by an acyl alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted,

(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted,

(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups,

(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group,

(v) by formation of an N-oxide or of a quaternary base;

(f) any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub-paragraph (a)) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say –

(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents,

(ii) by substitution at the 3-position with an alkyl substituent,

(iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;

(g) any compound structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say –

(i) by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents,

(ii) by substitution at the 3-position with an alkyl substituent,

(iii) by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure;

(ga) any compound (not being a compound specified in sub-paragraph (a)) structurally derived from 1-benzofuran, 2, 3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted in the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and

whether or not substituted in the ethylamino side -chain with one or more alkyl substituents;

(gb) any compound (not being benzyl(*α*-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2, 5-dimethoxy-*α*-methylphenethylamine, 2, 5-dimethoxy-*α*,4-dimethylphenethylamine, N-hydroxytenamphetamine, or a compound specified in sub-paragraph (a) or (c), by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent;

(h) 1-benzylpiperazine;

(i) any compound (not being a compound for the time being specified in Part 2 of this Schedule) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways –

(i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl substituents,

(ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl substituents;

(j) the following substances –

[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1, 2, 3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone

3-Dimethylheptyl-11-hydroxyhexahydrocannabinol

[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl] oxy-5, 6, 6a, 7, 8, 9, 10, 10a-octahydrophenanthridin-1-yl] acetate

9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[c]chromen-1-ol;

(k) any compound structurally derived from 3-(1-naphthoyl)indole, 3-(2-naphthoyl) indole, 1H-indol-3-yl-(1-naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(l) any compound structurally derived from 3-(1-naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(m) any compound structurally derived from 1-(1-naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,

cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(n) any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

(na) any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent;

(nb) any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

(nc) any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;

(nd) any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent;

(o) Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say –

(i) by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups,

(ii) by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group,

(iii) by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group;

(p) 1-phenylcyclohexylamine or any compound (not being eticyclidine, ketamine, phencyclidine, rolicyclidine, tenocyclidine or tiletamine) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say –

(i) by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups,

(ii) by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent,

(iii) by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents,

(iv) by replacement of the phenyl ring with a thienyl ring;

(q) any compound (not being clonitazene, etonitazene, nabilone, zafirlukast, or a compound for the time being specified in sub-paragraphs (j) to (nd)) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and where the modifications of the sub-structures are limited to any the following, that is to say –

(i) replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, or pyrazolo(3,4-b)pyridine,

(ii) replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl, or (tetrahydropyran-4-yl)methyl,

(iii) replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group,

(iv) replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1 amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, or piperazinyl.

2 Any stereoisomeric form of a substance specified in paragraph 1 above.

3 Any ester or ether of a substance specified in paragraph 1 (not being 2-((dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol).

3A Any ester or ether of a substance specified in paragraph 2.

4 Any salt of a substance specified in any of paragraphs 1 to 3 above.

5 Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4 above.

PART 2[2]

CONTROLLED DRUGS EXCEPTED FROM PART 1

1 The compounds referred to in Part 1, paragraph 1(d) of this Schedule are –

Alfentanil

Carfentanil

Lofentanil

Remifentanil

Sufentanil.

2 The compounds referred to in Part 1, paragraph 1(e) of this Schedule are –

Allylprodine

Alphameprodine

Alphaprodine

Anileridine

Betameprodine

Betaprodine

Hydroxypethidine

Properidine

Trimeperidine.

3 The compounds referred to in Part 1, paragraph 1(i) of this Schedule are –

1-(3-chlorophenyl)piperazine

1-(3-chlorophenyl)-4-(3-chlorophenyl)piperazine.

4

5

6

ENDNOTES

Table of Legislation History

Legislation	Year and Number	Commencement
Misuse of Drugs (Designation) (Jersey) Order 1989	R&O.7864	1 March 1989
Misuse of Drugs (Designation) (Amendment) (Jersey) Order 1991	R&O.8247	1 September 1991
Misuse of Drugs (Designation) (Amendment No. 2) (Jersey) Order 1992	R&O.8350	1 May 1992
Misuse of Drugs (Designation) (Amendment No. 3) (Jersey) Order 1999	R&O.9376	1 June 1999
Misuse of Drugs (Designation) (Amendment No. 4) (Jersey) Order 2002	R&O.55/2002	13 June 2002
Misuse of Drugs (Designation) (Amendment No. 5) (Jersey) Order 2003	R&O.8/2003	1 March 2003
Misuse of Drugs (Miscellaneous Amendments) (Jersey) (Order) 2010	R&O.94/2010	17 September 2010
Misuse of Drugs (Miscellaneous Amendments) (No. 2) (Jersey) Order 2012	R&O.106/2012	21 September 2012
Misuse of Drugs (Miscellaneous Amendments) (No. 3) (Jersey) Order 2013	R&O.75/2013	17 June 2013
Misuse of Drugs (Miscellaneous Amendments) (No. 4) (Jersey) Order 2013	R&O.166/2013	20 December 2013
Misuse of Drugs (Miscellaneous Amendments) (No. 5) (Jersey) Order 2014	R&O.93/2014	9 July 2014
Misuse of Drugs (Miscellaneous Amendments) (No. 6) (Jersey) Order 2016	R&O.20/2016	24 February 2016
Misuse of Drugs (Miscellaneous Amendments) (No. 7) (Jersey) Order 2018	R&O.147/2018	1 January 2019
Misuse of Drugs (Miscellaneous Amendments) (No. 8) (Jersey) Order 2019	R&O.49/2019	27 June 2019
Misuse of Drugs (Miscellaneous Amendments) (No. 9) (Jersey) Order 2021	R&O.145/2021	1 December 2021

Table of Renumbered Provisions

Original	Current
3	2
SCHEDULE PART I	SCHEDULE PART 1
PART II	PART 2

Table of Endnote References

[1] *Schedule* — *Part 1 amended by R&O.8247, R&O.8350, R&O.9376, R&O.55/2002, R&O.8/2003, R&O.94/2010, R&O.106/2012, R&O.75/2013, R&O.166/2013, R&O.93/2014, R&O.20/2016, R&O.147/2018, R&O.49/2019, R&O.145/2021*

[2] *Schedule* — *Part 2 amended by R&O.8/2003, R&O.94/2010, R&O.20/2016, R&O.147/2018, R&O.49/2019, R&O.145/2021*